Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel Purchases 1,000 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel acquired 1,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The stock was acquired at an average cost of $24.50 per share, for a total transaction of $24,500.00. Following the completion of the purchase, the director now directly owns 5,000 shares in the company, valued at $122,500. This trade represents a 25.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Anja Manuel also recently made the following trade(s):

• On Tuesday, November 12th, Anja Manuel purchased 4,000 shares of Hims & Hers Health stock. The shares were acquired at an average price of $26.94 per share, for a total transaction of $107,760.00.

Hims & Hers Health Stock Down 5.4 %

HIMS stock traded down $1.13 during trading on Friday, reaching $19.72. The stock had a trading volume of 13,139,313 shares, compared to its average volume of 9,171,635. Hims & Hers Health, Inc. has a one year low of $7.40 and a one year high of $30.44. The company’s 50 day moving average is $19.64 and its two-hundred day moving average is $18.78. The company has a market capitalization of $4.24 billion, a price-to-earnings ratio of 47.38 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period in the prior year, the company posted ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its position in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC increased its stake in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the last quarter. CWM LLC raised its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new position in Hims & Hers Health in the second quarter valued at approximately $111,000. Finally, Amalgamated Bank grew its holdings in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Piper Sandler reissued a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Truist Financial upped their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Canaccord Genuity Group raised their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $21.21.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.